DEVELOPMENT OF GUCY2C-TAC T CELLS FOR THE TREATMENT OF COLORECTAL CANCER

Tania Benatar*, Ling Wang, Thanyashanthi Nitya-Nootan, Heather MacGregor, Suzanna Prosser, Philbert IP, Prabha Lal, Stacey Xu, Laura Shaver, Sadhak Sengupta, Christopher Helsen, Andreas Bader.
Triumvira Immunologics, Inc., Hamilton, ON, Canada

Background The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit safe and durable anti-tumor responses. TAC01-HER2, a first-in-class TAC T product targeting HER2 (ERBB2), has entered a phase I/II clinical trial in patients with HER2-positive solid tumors. Here, we present the development of a new TAC T product targeting guanylyl cyclase 2C (GUCY2C) to treat colorectal cancer. GUCY2C belongs to a family of membrane-bound mucosal guanylate cyclase receptors and is selectively expressed on the apical brush border of intestinal epithelia, a site inaccessible to T cells. In cancer, however, GUCY2C is frequently overexpressed in primary and metastatic colorectal carcinomas and, thus, a preferred antigen for the specific targeting of tumor cells via TAC T cells.

Methods GUCY2C-TAC receptor functionality was characterized using a variety of in vitro and in vivo assays. In vitro assays were based on flow cytometric analysis of TAC surface staining, CD69 upregulation and T cell proliferation. Cytotoxicity was assessed via real-time microscopy co-culture assays. In vivo studies examined the anti-tumor effect of TAC-engineered T-cells against established GUCY2C-expressing tumor xenografts.

Results The GUCY2C-TAC receptor showed strong surface expression and specific activation when co-cultured with a variety of cancer cells expressing GUCY2C in vitro. Upregulation of the activation-induced CD69 marker was comparable with levels induced by activated control TAC T cells. Proliferation of GUCY2C-TAC T cells was induced by co-culture with naturally expressing GUCY2C target cell lines as well as GUCY2C-engineered cell lines. In vitro cytotoxicity assay demonstrated a strong anti-GUCY2C response and killing of GUCY2C-expressing target cell lines. No increases in T cell activation, proliferation and no cytotoxicity were observed in non-transduced T cells and GUCY2C-TAC T cells co-cultured with GUCY2C-negative target cells, indicating that the T cell response is specific to the GUCY2C antigen. Intravenous administration of GUCY2C-TAC T cells in mice carrying GUCY2C-positive tumor xenografts led to a sustained anti-tumor response.

Conclusions The in vitro and in vivo data confirm strong and specific activity of GUCY2C-targeted TAC T cells against GUCY2C-expressing tumor models and highlight the versatility of the TAC platform for therapeutic applications in solid tumors.

Ethics Approval AUP number 20-10-37, approved by McMaster University’s Animal Research Ethics Board.